Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid
Equine Veterinary Journal · 2025
DOI: 10.1111/evj.14531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Equine Veterinary Journal, 2025. Verfasst von Rodrigo Munevar Luque und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Ontario Veterinary College, Guelph, Ontario, Canada. Hauptthemen laut MEDLINE: Hyaluronic Acid, Horse Diseases, Mesenchymal Stem Cell Transplantation, Osteoarthritis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Equine Guelph.
Abstract (Originalsprache)
Background
Mesenchymal stromal cells (MSCs) are widely used to treat osteoarthritis (OA). Optimising dose, timing, and safety while comparing efficacy with standard therapies like hyaluronic acid (HA) is essential for their standardisation.
Objectives
To assess the safety and efficacy of equine umbilical cord‐derived (eCB) MSCs in client‐owned horses with fetlock or carpus OA. Study Design Prospective single‐blinded randomised clinical study.
Methods
Horses diagnosed with fetlock or carpus OA via intra‐articular (IA) anaesthesia were randomly assigned to receive either 10 or 20 million eCB‐MSCs in HA or 3 mL of HA alone (control). Subjective lameness examinations were performed at baseline, 3 weeks, and 6 weeks post‐treatment. Adverse reactions were evaluated 24–72 h post‐injection. Follow‐up surveys were sent to owners at 18 weeks.
Results
Twenty‐seven client‐owned horses were enrolled. No significant adverse reactions occurred. Lameness outcomes did not differ significantly between treatment groups at 3 or 6 weeks ( p > 0.05), though all groups showed improvement over time ( p < 0.05). Median lameness change at 6 weeks was −1.5 (0.5) grades for HA, −2.0 (1.0) for 10‐MSC + HA, and −2.0 (1.0) for 20‐MSC + HA. Although return‐to‐work rates were not significantly different ( p > 0.05), both MSC + HA groups had higher return rates to the same or higher work levels than HA‐only (8 out of 9, 7 out of 9, and 5 out of 9, respectively). Main Limitations Small sample size.
Conclusions
The study aimed to assess MSC treatment safety and efficacy. Higher return‐to‐exercise rates were expected in the MSC groups at 18 weeks, but unexpectedly high rates in the HA group may have led to underpowering. A post hoc calculation suggests 30 horses per group would be needed to detect significant differences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Ontario Veterinary College, Guelph, Ontario, Canada.
- Rivendell Equine Veterinary Services, Grand Valley, Ontario, Canada.
- Department of Clinical Studies, Ontario Veterinary College, Guelph, Ontario, Canada.
ORCID-Profile: Rodrigo Munevar Luque, Judith Koenig
Förderung
- Equine Guelph
Zitieren
APA
Luque, R. M., Henderson, B., McCorkell, T. C., Alizadeh, A. H., Russell, K. A., Koch, T. G., & Koenig, J. (2025). Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid. Equine Veterinary Journal. https://doi.org/10.1111/evj.14531
Vancouver
Luque RM, Henderson B, McCorkell TC, Alizadeh AH, Russell KA, Koch TG, et al. Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid. Equine Veterinary Journal. 2025. doi:10.1111/evj.14531
BibTeX
@article{Luque2025,
author = {Luque, Rodrigo Munevar and Henderson, Bri and McCorkell, Terence Connor and Alizadeh, Amir Hamed and Russell, Keith A and Koch, Thomas G and Koenig, Judith},
title = {Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid},
journal = {Equine Veterinary Journal},
year = {2025},
doi = {10.1111/evj.14531}
}
EUVIMED